serp-1

Serp-1 is a recombinant serine protease inhibitor (serpin) derived from the myxoma virus. It acts as an immune-modulating protein by binding to and inhibiting tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), plasmin, factor X, and thrombin. Through these actions, Serp-1 regulates endogenous thrombolysis and reduces inflammation by preventing activation of the urokinase-plasminogen activator receptor (uPAR). This inhibition limits inflammatory cell migration, adhesion to endothelium, matrix metalloproteinase-mediated invasion of vessel walls, and proliferation at sites of injury. Serp-1 has been studied as an adjunctive therapy in acute coronary syndromes during percutaneous coronary intervention (PCI) and has shown potential in reducing post-procedural myocardial necrosis without increasing adverse events. It is also being investigated for its ability to inhibit M1 macrophage migration in autoimmune diseases such as systemic lupus erythematosus with diffuse alveolar hemorrhage[1][3][5][6][7].

Other names

Serp-1Serp1Serp 1